文献速递免疫规划传染病防控与疫情报告

英国布里斯托尔因急性下呼吸道感染住院成人中肺炎链球菌血清型的监测

Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.
PubMed 文献 · Vaccine · 2024-02-08

一项前瞻性队列研究纳入英国布里斯托尔两家医院2021年11月至2022年11月因急性下呼吸道疾病住院的成人,通过血培养、BinaxNOW™和血清型特异性尿抗原检测发现,肺炎链球菌在CAP+RAD+、CAP+RAD-和NP-LRTI中均可检出,且相当比例由疫苗血清型引起。

要点

  • 在2445名提供尿液的LRTI住院成人中,280名(11.5%)检出肺炎链球菌。
  • CAP+RAD+、CAP+RAD-和NP-LRTI中肺炎链球菌检出率分别为15.0%、11.1%和8.1%。
  • 280例肺炎链球菌感染中,75.0%由PCV20+6C/15C血清型引起,81.4%由PPV23+15C血清型引起。

核心结论

  • 在因呼吸道感染住院的成人中,肺炎链球菌是所有亚组(包括CAP+RAD-和NP-LRTI)的重要病原体。
  • 尽管在≥65岁成人中使用PPV23已20年且婴儿使用PCV已17年产生群体保护,疫苗血清型肺炎链球菌病仍导致相当比例的成人LRTI住院。
  • 成人直接接种高价PCV可能减轻肺炎链球菌病负担(作者认为)。

研究设计与样本

  • 前瞻性队列研究,纳入英国布里斯托尔两家医院2021年11月至2022年11月所有≥18岁因急性下呼吸道疾病住院的成人。
  • LRTI患者分为影像学确诊的CAP(CAP+/RAD+)、临床诊断但无影像学确诊的CAP(CAP+/RAD-)和NP-LRTI。
  • 肺炎链球菌通过血培养、BinaxNOW™和血清型特异性尿抗原检测识别。

主要发现

  • 12083例aLRTD住院中,10026例为LRTI,2445例提供尿液:CAP+RAD+ 1097例、CAP+RAD- 207例、NP-LRTI 1141例。
  • 中位年龄71.1岁(IQR 57.9-80.2),Charlson合并症指数4(IQR 2-5);2.7%需重症监护,4.4%在住院30天内死亡。
  • 280/2445(11.5%)检出肺炎链球菌;≥65岁和18-64岁成人中分别为12.9%(198/1534)和9.0%(82/911)。
  • CAP+RAD+中165/1097(15.0%)、CAP+RAD-中23/207(11.1%)、NP-LRTI中92/1141(8.1%)检出肺炎链球菌。
  • 280例肺炎链球菌中,102例(36.4%)由PCV13+6C血清型引起,115例(41.7%)由PCV15+6C引起,210例(75.0%)由PCV20+6C/15C引起,228例(81.4%)由PPV23+15C引起;最常见血清型为8(78例,27.9%)、7F(25例,8.9%)、3(24例,8.6%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pneumococcus remains a major cause of adult lower respiratory tract infections (LRTI). Few data exist on the relative contribution of serotypes included in pneumococcal vaccines to community-acquired pneumonia (CAP) and non-pneumonic (NP) LRTI. We measured the burden of all and vaccine-serotype pneumococcal respiratory infection following SARS-CoV-2 emergence to inform evidence-based vaccination policy. METHODS: A prospective cohort study at two Bristol hospitals (UK) including all adults age ≥ 18-years hospitalised with acute lower respiratory tract disease (aLRTD) from Nov2021-Nov2022. LRTI patients were classified as: a) radiographically-confirmed CAP (CAP+/RAD+), b) clinically-diagnosed CAP without radiological confirmation (CAP+/RAD-), or c) NP-LRTI. Pneumococcus was identified by blood culture, BinaxNOW™and serotype-specific urine antigen detection assays (UAD). RESULTS: Of 12,083 aLRTD admissions, 10,026 had LRTI and 2,445 provided urine: 1,097 CAP + RAD+; 207 CAP + RAD-; and 1,141 NP-LRTI. Median age was 71.1y (IQR57.9-80.2) and Charlson comorbidity index = 4 (IQR2-5); 2.7 % of patients required intensive care, and 4.4 % died within 30-days of hospitalisation. Pneumococcus was detected in 280/2445 (11.5 %) participants. Among adults aged ≥ 65y and 18-64y, 12.9 % (198/1534) and 9.0 % (82/911), respectively, tested pneumococcus positive. We identified pneumococcus in 165/1097 (15.0 %) CAP + RAD+, 23/207 (11.1 %) CAP + RAD-, and 92/1141 (8.1 %) NP-LRTI cases. Of the 280 pneumococcal cases, 102 (36.4 %) were due to serotypes included in PCV13 + 6C, 115 (41.7 %) in PCV15 + 6C, 210 (75.0 %) in PCV20 + 6C/15C and 228 (81.4 %) in PPV23 + 15C. The most frequently identified serotypes were 8 (n = 78; 27.9 % of all pneumococcus), 7F (n = 25; 8.9 %), and 3 (n = 24; 8.6 %). DISCUSSION: Among adults hospitalised with respiratory infection, pneumococcus is an important pathogen across all subgroups, including CAP+/RAD- and NP-LRTI. Despite 20-years of PPV23 use in adults ≥ 65-years and herd protection due to 17-years of PCV use in infants, vaccine-serotype pneumococcal disease still causes a significant proportion of LRTI adult hospitalizations. Direct adult vaccination with high-valency PCVs may reduce pneumococcal disease burden.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hyams C, Lahuerta M, Theilacker C, et al. Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK. Vaccine. 2024. PMID: 38336560. doi:10.1016/j.vaccine.2024.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。